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Abstract
AIM
To build a regional database of chronic patients to define 
the clinical epidemiology of hepatitis B virus (HBV)-
infected patients in the Tuscan public health care system.
METHODS
This study used a cross-sectional cohort design. We eva-
luated chronic viral hepatitis patients with HBV referred to 
the outpatient services of 16 hospital units. Information in 
the case report forms included main demographic data, 
blood chemistry data, viral hepatitis markers, instrumental 
evaluations, and eligibility for treatment or ongoing therapy 
and liver transplantation. 
RESULTS
Of 4015 chronic viral hepatitis patients, 1096 (27.3%) 
were HBV infected. The case report form was correctly 
completed for only 833 patients (64% males, 36% fe-
males; mean age 50.1 ± 15.4). Of these HBV-infected 
patients, 73% were Caucasian, 21% Asian, 4% Central 
African, 1% North African and 1% American. Stratifying 
patients by age and nationality, we found that 21.7% 
of HBV-infected patients were aged < 34 years (only 
2.8% were Italian). The most represented routes of 
transmission were nosocomial/dental procedures (23%), 
mother-to-child (17%) and sexual transmission (12%). 
The most represented HBV genotypes were D (72%) and 
A (14%). Of the patients, 24.7% of patients were HBeAg 
positive, and 75.3% were HBeAg negative. Of the HBV 
patients 7% were anti-HDV positive. In the whole cohort, 
26.9% were cirrhotic (35.8% aged < 45 years), and 47% 
were eligible for or currently undergoing treatment, of 
whom 41.9 % were cirrhotic. 
CONCLUSION
Only 27.3% of chronic viral hepatitis patients were HBV 
infected. Our results provide evidence of HBV infection 
in people aged < 34 years, especially in the foreign 
population not protected by vaccination. In our cohort of 
patients, liver cirrhosis was also found in young adults. 
Key words: Hepatitis B virus infection; Liver fibrosis; 
Cirrhosis; Public health; Epidemiology
© The Author(s) 2018. Published by Baishideng Publishing 
Group Inc. All rights reserved.
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Core tip: Although the introduction of a vaccine against 
hepatitis B virus (HBV) has been highly effective in 
reducing the incidence and prevalence of HBV infection in 
many countries, an estimated 257 million people worldwide 
are chronically infected. In 2015, WHO published the 
guidelines for prevention, care and treatment of HBV 
infected people promoting treatment based on noninvasive 
assessment. This real-world large-scale cohort study 
provides appropriate planning for public health programs, 
as well as the specific characteristics of patients, thus 
contributing to the successful, efficient translation of new 
knowledge to management and treatment of HBV patients 
to eradicate HBV.
Stasi C, Silvestri C, Berni R, Brunetto MR, Zignego AL, Orsini C, 
Milani S, Ricciardi L, De Luca A, Blanc P, Nencioni C, Aquilini 
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R, Carrai P, Ricchiuti A, Giusti M, Almi P, Cozzi A, Carloppi S, 
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INTRODUCTION
While the introduction of an effective vaccine has be­
en highly effective in reducing the incidence and pre­
valence of hepatitis B virus (HBV) infection in many 
countries, an estimated 257 million people worldwide 
are chronically infected[1]. 
HBV prevalence is > 8% in parts of sub­Saharan 
Africa. An intermediate prevalence (2%­8%) is present 
in some regions of the eastern Mediterranean, Central 
Asia, Southeast Asia, China, parts of South America and 
some European countries (Albania, Bulgaria, Romania, 
Turkey and Italy). There is a low prevalence (< 2%) in 
parts of North America and in some European countries 
(Belgium, the Czech Republic, Denmark, France), as 
well as Australia and New Zealand[2].
High levels of viremia, or the infection contracted 
at a young age (affecting mainly males) are associated 
with an increased risk of death or of developing hep­
atocellular carcinoma[3]. In 2015, hepatitis B resulted in 
887000 deaths, mostly from complications (including 
cirrhosis and hepatocellular carcinoma)[1].
In 2015, WHO published guidelines for the preve­
ntion, care and treatment of persons with chronic HBV 
infection. These promote the use of simple, noninvasive 
tests to assess liver disease stage and eligibility for 
treatment. For adult patients in countries with limited 
resources, the test for ratio of aspartate aminotransferase 
to platelets (APRI) is recommended as a noninvasive 
diagnostic to assess the presence of cirrhosis (APRI 
score > 2), while transient elastography (e.g., fibroscan) 
or fibrotest are recommended in countries where th­
411WJH|www.wjgnet.com
ese tests are available and cost constraints are not 
significant. These guidelines are based on a public health 
approach to the use of antiviral drugs for the treatment 
of chronic HBV. Such an approach considers the feasibility 
and effectiveness of treatment, even in countries with 
limited resources­for example, in areas where diagnostic 
methods such as HBV DNA and liver biopsy are unable to 
be used[4].
According to the latest Italian recommendations[5], 
treatment with nucleoside or nucleotide analogues is 
indicated in the following instances: HBeAg­positive 
patients with moderate or severe fibrosis who have fai­
led seroconversion after a cycle of Peg­IFN, for whom 
treatment with Peg­IFN is not indicated at diagnosis; in 
HBeAg­negative patients with moderate or severe fibrosis 
who have already been treated with Peg­IFN without 
success or those for whom treatment with PegIFN is 
not indicated at diagnosis; in HBeAg­positive or HBeAg­
negative patients who (for family, work or social reasons) 
are unable to practice or do not accept Peg­IFN therapy; 
in HBeAg­positive or HBeAg­negative patients with 
compensated or decompensated cirrhosis, regardless of 
the likelihood of seroconversion, serum HBV DNA levels 
and ALT values.
The aim of this study was to build a regional dat­
abase of patients diagnosed with chronic HBV infection 
in specialised outpatient services in our region to define 
the clinical epidemiology of HBV­infected patients in the 
Tuscan public health care system.
MATERIALS AND METHODS
This prospective observational study is fully in line with 
the objectives of the National Plan for the Prevention 
of Viral Hepatitis, in particular the Address Line 1 
(LI 1)­Epidemiology, which seeks to “define the ep­
idemiology of viral hepatitis B and C and to strengthen 
surveillance systems”. Objective 3 is of particular focus: 
It outlines the importance of the quality of reporting 
system data and the monitoring of HBV and HCV as 
acute or chronic infections[6]. 
All patients with HBV­related chronic liver disease 
referred to the hepatology outpatient services of 16 
hospital units from January 1, 2015, to December 31, 
2015, and who agreed to participate in the study, were 
evaluated. These 16 hospital units were: Hepatology 
Unit, University Hospital of Pisa, Pisa, Italy; Centre for 
Systemic Manifestations of Hepatitis Viruses (MaSVE), 
Internal Medicine and Liver Unit, Department of Exp­
erimental and Clinical Medicine, Careggi University 
Hospital, Florence, Italy; Gastroenterology Research 
Unit, Department of Experimental and Clinical Biomedical 
Sciences Mario Serio, Careggi University Hospital, 
Florence, Italy; Infectious Disease Unit, Hospital of Lucca, 
Italy; Infectious Diseases Unit, Siena University Hospital, 
Siena, Italy; Infectious Disease Unit, S. Maria Annunziata 
Hospital, Florence, Italy; Infectious Disease Unit, Hospital 
of Grosseto, Italy; Infectious Disease Unit, Hospital of 
Prato, Italy; Infectious and Tropical Diseases Unit, Careggi 
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University Hospital, Florence, Italy; Gastroenterology 
and Metabolic Disorders, Cisanello University Hospital, 
Pisa, Italy; Gastroenterology Unit, Department of 
Translational Research and New Technologies in Medicine 
and Surgery, Cisanello University Hospital of Pisa, Pisa, 
Italy; Liver Surgery and Transplantation Unit, Cisanello 
University Hospital, Pisa, Italy; Internal Medicine Unit, 
San Jacopo Hospital, Pistoia, Italy; Infectious Diseases 
and Hepatology Unit, University Hospital of Siena, Siena, 
Italy; Gastroenterology Unit, San Giuseppe Hospital, 
Empoli, Italy; and Internal Medicine and Liver Unit, 
Careggi University Hospital, Florence, Italy.
Study design
The Regional Health Agency of Tuscany provided all units 
with a computerised clinical database to collect the main 
socio­demographic, clinical and treatment data for all 
patients with chronic HCV and HBV infection admitted 
at each centre. A record was created for each patient 
containing his or her main personal data, blood chemistry 
data, viral hepatitis markers, HCV­RNA and HBV­
DNA viral load, histology and instrumental evaluation 
(FibroScan®, liver ultrasound), previous treatment (with 
outcome), eligibility for treatment, or therapy already in 
progress, and liver transplantation details.
Liver ultrasound and elastography are among the 
main diagnostic procedures used in patients with chronic 
hepatitis. Liver ultrasound allows clinicians to diagnose 
and monitor chronic liver diseases, including the diagnosis 
of liver tumours and the identification of signs of portal 
hypertension. Liver surface irregularities detected by 
ultrasound techniques define the presence of micro­ and 
macronodules and are considered the most sensitive 
and reproducible signs of liver cirrhosis[7]. Elastography 
characterises the properties and mechanical response 
of tissues, measuring their stiffness[8]. Elastography 
is currently used to determine clinical priorities based 
on the estimated fibrosis stage. In HBV naïve patients 
with normal ALT, the cut­offs used were < 6 kPa (no 
significant fibrosis), 6­9 kPa (grey area), and > 9 kPa 
(severe fibrosis/cirrhosis). In HBV­naïve patients with 
elevated ALT (but < 5 × ULN), the cut offs used were < 
6 kPa (no significant fibrosis), 6­12 kPa (grey area), and 
> 12 kPa (severe fibrosis/cirrhosis)[9].
To estimate the number of patients with more se­
vere liver disease, we considered those patients with 
a Child­Pugh score (used only to assess the severity 
of liver cirrhosis), and/or with a liver stiffness either > 
9 kPa (normal ALT) or > 12 kPa (elevated ALT)[9] at 
elastography, and/or with a histological diagnosis of 
cirrhosis (METAVIR score equal to F4 or Ishak equal 
to S5­6), and/or with a nodular structure of the liver 
identified by ultrasound examination. Duplicate cases 
were excluded.
The demographic data were appropriately encrypted 
in the database. The software not only allowed the 
research team to include guided and controlled info­
rmation using a combo­box but also to export files ready 
to be sent.
The exported file (containing the “anonymized” da­
ta) was sent from the system to the Regional Health 
Agency of Tuscany via a secure channel (SSL). After 
logging in and connecting to the Agency’s web page, 
the user was then able to upload the file.
The research topic was described to the patients. 
The local Ethics Committee approved the study. Each 
participant gave written informed consent prior to the 
study, in accordance with the principles of the Declaration 
of Helsinki (Sixth Revision, Seoul 2008). 
Statistical analysis
All data were validated, checking for out­of­range values 
and values that were logically inconsistent were handled. 
All results are expressed as mean ± SD. The numerical 
comparison of continuous data was performed using the 
Student’s t­test for unpaired and for paired samples with 
Bonferroni correction, after checking similar variances 
in the groups by Levine’s test for equality of variances. 
To avoid the potential bias related to the missing data, 
the analysis of the variables was conducted only on the 
completed fields. 
Statistical significance was set at a value of P < 
0.05. Statistical analysis was obtained using statistical 
software Stata 12 (College Station, TX, United States).
RESULTS
Demographic and epidemiological features 
A total of 23 hepatology units were invited to participate 
in the study. Data were obtained from 16 hospital 
units for a total of 4654 cases of chronic HBV and HCV 
infections. Diagnoses were specified for 4015 (86.3%) 
patients, of whom 1096 (27.3%) were HBV infected 
(Figure 1). However, the case report form was correctly 
completed for only 833 patients (64% males, 36% 
females; mean age 50.1 ± 15.4). For HBV patients, 
73% were Caucasian, 21% Asian, 4% Central African, 
1% North African and 1% American. Of these HBV­
infected patients, 106 (12.7%) were referred to the 
clinics for the first time during the period in question. 
Table 1 shows the patients stratified by age and gender.
Analysis of the calendar year of diagnosis and of the 
first access to specialised services reveals that about 
98.1% of these cases occurred after 1990. 
Stratifying patients by age and nationality, we found 
that 21.7% of HBV­infected patients were aged < 34 
years (only 2.8% were Italian). Table 2 shows the most 
represented routes of transmission were nosocomial/
dental procedures (23%), mother­to­child (17%) and 
sexual transmission (12%). 
Clinical data
The most represented HBV genotypes were D (72%) and 
A (14%), shown in Table 3, seen in 135 HBV patients. 
The total population displayed the following par­
ameters: mean ALT = 59.84 ± 108.49 IU/L; mean AST 
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= 48.20 ± 87.02 IU/L; mean Platelets = 195.23 ± 72.13 
cells/L. The number of patients with PLT < 100000 was 
31. In the population, 24.7% of HBV patients were HBeAg 
positive, 75.3% were HBeAg negative, and 7% were anti­
HDV positive. 
In non­treated HBeAg and anti HBeAg positive pa­
tients, the HBV DNA levels were 7.26 × 107 ± 1.71 × 
108 and 8358838 ± 2.71 × 107 UI/mL, respectively.
In non­treated HBeAg and anti­HBeAg­positive 
patients, the ALT levels were 42.05 ± 29.70 U/L and 
33.96 ± 33.49 U/L, respectively.
Staging of liver disease
A total of 89 HBV patients underwent liver biopsy. Of 
these, 66 also had elastography, with 45% of total 
liver biopsies performed before 2007 (i.e., before liver 
elastography was used in clinical practice). Of 89 patients 
underwent liver biopsy, 70% were evaluated with an 
Ishak score (supplementary material), providing a better 
definition of liver fibrosis compared to METAVIR score. 
Twenty­three patients underwent liver biopsy alone, while 
283 underwent elastography, with the latter performed 
exclusively after 2008.
Ultrasound examination revealed liver structure alt­
eration in 29.4% of cases, and the presence of a nodular 
structure in 12%. 
In the whole cohort, 26.9% of patients were cirrhotic 
(35.8% were aged < 45 years). The Child­Pugh score 
was specified in 156 patients. Most cirrhotic patients 
were classified as Child­Pugh Class A (n = 150, 96.2%), 
with an early stage severity of liver cirrhosis, with 4 
classified as Child B (2.5%) and 2 as Child C (n = 1.3%). 
One hundred and six patients displayed signs of portal 
hypertension, which mostly occurred in those < 45 years 
(26%). Eight patients received liver transplantations. 
Forty­seven percent of patients were either eligible for or 
currently undergoing treatment, of whom 41.9% were 
cirrhotic. Dividing the cohort into treated (n = 162) and 
untreated HBeAg­positive patients (n = 182), we found 
significant differences between liver stiffness values (7.83 
± 3.56 vs 5.3 ± 2.3, P = 0.02). Similar differences were 
observed (7.84 ± 5.05 vs 4.82 ± 1.88, P < 0.001) when 
dividing the cohort into treated (n = 163) and untreated 
anti­HBeAg­positive patients (n = 181).
DISCUSSION
To our knowledge, this study involves the largest cohort 
of HBV patients in Italy. HBV infection was responsible 
for 27.3% of cases of chronic liver disease, whereas a 
previous study by Sagnelli et al[10] found an HBV pre­
valence of 20.2%.
We also found HBV­infected patients in those aged 
< 34 who would normally be covered by vaccination. 
Analysis of the nationality of HBV­infected patients hig­
hlights the prevalence of infection in the non­Italian 
population (only 2.8% of Italians were infected). Similar 
data was found in a previous study conducted in an 
industrialised city in the Tuscany region[11]. Further eff­
orts are needed to improve vaccination coverage for 
Table 1  Percentage of hepatitis B virus infected patients stratified by age group n  (%)
Age group Males Females Total
≤ 34    54 (18.3)    46 (27.9)  100 (21.7)
35-44    60 (20.3)    26 (15.7)    86 (18.7)
45-54    68 (23.1)    33 (20.0)  101 (22.0)
55-64    58 (19.7)    27 (16.4)    85 (18.5)
65-74    36 (12.2)    22 (13.3)    58 (12.6)
> 75  19 (6.4)  11 (6.7)  30 (6.5)
Total 295 (100) 165 (100) 460 (100)
Missing 479
23 hospital units
16 hospital units partecipated
A total of 4654 cases
Diagnosis for 4015 cases
1096 HBV cases 2919 HCV cases
Figure 1  A total of 23 hepatology units were invited to enrol patients in the study, but 16 hepatology units have participated for a total of 4654 cases of 
chronic viral hepatitis. The diagnoses were specified for 4015 patients, of whom 1096 (27.3%) were hepatitis B virus infected. HBV: Hepatitis B virus; HCV: Hepatitis 
C virus.
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non­infected and non­vaccinated immigrants who are 
susceptible to infection.
According to national data on risk factors associated 
with the HBV infection in the Integrated Epidemiological 
System of Viral Acute Hepatitis (SEIVA), nosocomial/
dental procedures (23%) are some of the most rep­
resented risk factors for HBV transmission, followed 
by mother­to­child (17%) and sexual transmission 
(12%). Recently, cosmetic treatment with percutaneous 
exposure (28% of patients), sexual exposure (24.7%), 
and dental therapy (11.5%) have been recognized as 
the main risk factors in acute viral hepatitis B in Italy. 
The risk of maternal­infant transmission is related to the 
mother’s HBV replicative status (90% correlation with 
HBeAg­positive mothers compared to 10%­20% for 
HBeAg­negative mothers)[12]. Many studies[13­16] have 
highlighted that pregnant women in particular with high 
levels of HBV DNA (more elevated in HBeAg positive 
patients compared to HBeAg­negative patients) have 
an increased risk of transmitting infection. As recently 
shown by Sagnelli et al[17], the screening of pregnant 
women to detect circulating HBsAg and prophylaxis 
procedures for new­born babies, the universal va­
ccination against HBV infection introduced in 1991, and 
national media campaigns against HIV infection are co­
nsidered the main reasons for the significant reduction 
in this type of transmission. Heterosexual (and, to a 
greater extent, homosexual) activity remain significant 
means of transmission. A study of Zuccaro et al[14] for 
an HBV cohort of 103 patients in 15 Italian hospital units 
showed a high prevalence of sexual transmission. In a 
study by Hahné et al[15], HBsAg prevalence estimates 
in men who have sex with men (MSM) ranged from < 
1% to 4% in 3 of the 34 countries. This prevalence was 
22 times higher than that of the general population for 
countries with available data[15].
As reported by Liaw et al[16], HBV genotype D is 
predominant in Mediterranean countries. In line with 
this finding, our study found that the most represented 
HBV genotype were D (72%), followed by A (14%). As 
concerns the potential bias of missing data, the statistical 
advantage of data that are missing completely at random 
is that the estimated parameters are not biased by the 
absence of the data.
To our knowledge, this is one of the few Italian st­
udies to consider both infection rates and liver fibrosis 
stage based on international guidelines for a large cohort 
of patients.
We found a higher prevalence of HBeAg positive 
patients (24.7%) compared to Sagnelli et al[10] (7.2%) 
and a lower anti­HDV prevalence (7% vs 11.9%). It 
is well established that ongoing HBV replication or the 
presence of HBeAg may accelerate the progression of 
liver fibrosis. In a study of the natural course of HBV 
infection during the HBeAg­positive phase, Chu et al[18] 
showed that the annual incidence of cirrhosis was 0.5%, 
and the cumulative probability of cirrhosis after 17 years 
was 12.6%. Hence, age at anti­HBe seroconversion 
and hepatitis relapse were independent risk factors for 
cirrhosis. In particular, deferred HBeAg seroconversion 
(patients > 40 years) were associated with an increased 
risk of cirrhosis[18]. Moreover, HDV coinfection is associated 
with an accelerated progression towards liver cirrhosis, 
decompensation in existing cases of cirrhosis, and an 
increased risk of hepatocellular carcinoma[19].
In our cohort, almost all untreated patients were 
represented by inactive HBV carriers (HBV DNA < 2000 
IU/mL), and by patients in an immune­tolerant phase (HBV 
DNA > 20000 IU/mL) with liver stiffness measurements 
< 6 kPa and normal ALT. These results are in agreement 
with national guidelines for treatment[5]. A study of 361 
patients with inactive HBeAg­negative chronic hepatitis 
B patients demonstrated that liver fibrosis progression is 
rare given serum HBV DNA < 20000 IU/mL and normal 
ALT[21]. Brunetto et al[20] demonstrated that after a mean 
follow­up of six years, anti­HBe positive chronic hepatitis 
B progressed to cirrhosis in 45% of patients, with end­
stage complications occurring in 24% of those presenting 
with cirrhosis. These outcomes seem to be associated 
with older age and persistent viral replication or hepatitis 
exacerbations in chronic hepatitis or cirrhotic patients. 
A recent study by Olivieri et al[22] showed that HBeAg­
negative HBsAg­carriers with baseline HBV­DNA ≤ 20000 
IU/mL, and normal transaminases were associated with 
transition to inactive carrier status in 43% of low­viremic 
active carriers, and to occult HBV infection in 20% of 
inactive carrier, within five years.
We found that almost all patients with liver stiffness 
> 6 kPa were treated. There are several instances 
of evidence showing that antiviral therapy stops the 
progression of liver fibrosis and induces fibrosis reg­
ression. A recent study by Stasi et al[23] conducted in 
anti­HBeAg­positive patients before and during antiviral 
treatment using liver stiffness measurements with 
Table 2 Distribution of hepatitis B virus transmissions-
multiple-choice analysis n  (%)
Routes of transmission Distribution
Intravenous drug users 15 (3.5)
Coagulation factors/blood transfusions 26 (6.0)
Sexual transmission   53 (12.3)
Piercing and tattooing   9 (2.1)
Vertical transmission   73 (16.9)
Nosocomial/dental cure 101 (23.4)
Undefined 255 (59.0)
Table 3  Distribution of the major hepatitis B virus genotypes 
n  (%)
Genotypes Distribution
A    19 (14.1)
B    4 (3.0)
C    4 (3.0)
D    97 (71.9)
E    5 (3.6)
F    6 (4.4)
Total 135 (100)
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transient elastography at different time points to assess 
changes in liver fibrosis showed a statistically significant 
reduction in stiffness values at 18 and 24 mo from those 
observed prior to therapy.
In the whole cohort, 26.9% were cirrhotic patients; it 
should be stressed here that 35.8% of these were aged 
< 45 years. The majority of cirrhotic patients showed 
signs of portal hypertension (43%). This data was 
different to that of Sagnelli et al[10] for a cohort of 513 
HBV patients, 24% of whom had liver cirrhosis.
In conclusion, our data showed that 27.3% of chronic 
viral hepatitis patients were HBV infected. Evidence of HBV 
infection in people aged < 34 years was apparent, especially 
in the foreign population not protected by vaccination. The 
main routes of transmission were consolidated by data 
reported in several other studies. In our cohort of patients, 
we found an elevated prevalence of HBeAg­positive patients. 
In line with other Italian data, we found a high prevalence 
of liver cirrhosis in young adults. Antiviral treatment seems 
to be fully in line with national guidelines. Further efforts 




While the introduction of an effective vaccine has been highly effective in 
reducing the incidence and prevalence of hepatitis B virus (HBV) infection in 
many countries, an estimated 257 million people worldwide are still chronically 
infected. In 2015, WHO published guidelines for the prevention, care and 
treatment of persons with chronic HBV infection. These promote the use 
of simple, noninvasive tests to assess liver disease stage and eligibility for 
treatment. 
Research motivation
Few data are currently available concerning the real-word large-scale staging 
and treatment of HBV patients followed in specialised outpatient services. The 
knowledge of the specific characteristics of patients could lead to appropriate 
planning for public health programs, thus contributing to the successful, efficient 
translation of this knowledge to management and treatment of HBV patients to 
eradicate HBV.
Research objectives 
The main objective of this study was to build a regional database of patients 
diagnosed with chronic HBV infection in specialised outpatient services in our 
region to define the clinical epidemiology of HBV-infected patients in the Tuscan 
public health care system.
Research methods
This prospective observational study is fully in line with the objectives of the 
National Plan for the Prevention of Viral Hepatitis, in particular with those 
outlining the importance of the quality of reporting system data and of the 
monitoring of HBV and hepatitis C virus as acute or chronic infections. This 
study used a cross-sectional cohort design to evaluate all patients with HBV-
related chronic liver disease referred to the hepatology outpatient services of 
16 hospital units from January 1, 2015, to December 31, 2015. A computerised 
clinical database was used to collect the main socio-demographic, clinical and 
treatment data for all patients with chronic HBV infection admitted at each 
centre. The exported file (containing the “anonymized” data) was then sent to 
the Regional Health Agency of Tuscany via a secure channel (SSL). 
Research results
The results of this study demonstrated that 27.3% of chronic viral hepatitis 
patients were HBV infected. Of these HBV-infected patients, 73% were 
Caucasian, 21% Asian, 4% Central African, 1% North African and 1% American. 
Stratifying patients by age and nationality, we found that 21.7% of HBV-infected 
patients were aged < 34 years. Among these only 2.8% were Italian. The most 
represented routes of transmission were nosocomial/dental procedures (23%), 
mother-to-child (17%) and sexual transmission (12%). The most represented 
HBV genotypes were D (72%) and A (14%). Of the patients, 24.7% were 
HBeAg positive, and 75.3% were HBeAg negative. Of the HBV patients, 7% 
were anti-HDV positive. In the whole cohort, 26.9% were cirrhotic (35.8% aged 
< 45 years), and 47% were eligible for or currently undergoing treatment, of 
whom 41.9% were cirrhotic. 
Research conclusions
The informatization of clinical data and the real-word large-scale staging and 
treatment of these kinds of patients would allow health planners to assign 
specific healthcare resources to targeted populations. This observational 
research may provide a public health opportunity to screen and treat specific 
groups of patients. In particular, to eradicate HBV infection further efforts are 
necessary to increase vaccine coverage in immigrant populations. 
Research perspectives
Based on the data collected in the course of this investigation, it is necessary 
to implement a series of preventive measures and strengthen the entire care 
process to eliminate, or at least reduce, risk factors for HBV infection and 
progression toward advanced liver fibrosis stages and to adopt care protocols 
suitable for immigrant populations.
REFERENCES
1  World Health Organization. Hepatitis B. Fact sheet. Reviewed 
July 2017. Available from: URL: http://www.who.int/mediacentre/
factsheets/fs204/en/
2  Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. 
Estimations of worldwide prevalence of chronic hepatitis B virus 
infection: a systematic review of data published between 1965 
and 2013. Lancet 2015; 386: 1546-1555 [PMID: 26231459 DOI: 
10.1016/S0140-6736(15)61412-X]
3  Taylor BC, Yuan JM, Shamliyan TA, Shaukat A, Kane RL, 
Wilt TJ. Clinical outcomes in adults with chronic hepatitis B in 
association with patient and viral characteristics: A systematic 
review of evidence. Hepatology 2009; 49: S85-S95 [PMID: 
19399797 DOI: 10.1002/hep.22929]
4  World Health Organization. Guidelines for the prevention, 
care and treatment of persons with chronic hepatitis B infection. 
Available from: URL: http://www.who.int/hiv/pub/hepatitis/
hepatitis-b-guidelines/en/
5  Brunetto MR, Bruno R, Di Marco V, Taliani G, Gaeta GB. Terapia 
della Epatite Cronica B: aggiornamento 2015 delle raccomandazioni 
Italiane. Available from: URL: http://www.webaisf.org/media/36572/
raccomandazioni_hbv_aisf-simit_2016.pdf
6  Ministero della Salute. Piano Nazionale per la prevenzione delle 
epatiti virali da virus B e C. Available from: URL: https://www.
salute.gov.it/imgs/C_17_pubblicazioni_2437_allegato.pdf
7  Stasi C, Milani S. Evolving strategies for liver fibrosis staging: 
Non-invasive assessment. World J Gastroenterol 2017; 23: 
191-196 [PMID: 28127192 DOI: 10.3748/wjg.v23.i2.191]
8  Stasi C, Milani S. Non-invasive assessment of liver fibrosis: 
Between prediction/prevention of outcomes and cost-effectiveness. 
World J Gastroenterol 2016; 22: 1711-1720 [PMID: 26819535 
DOI: 10.3748/wjg.v22.i4.1711]
9  European Association for Study of Liver. Asociacion Lati-
noamericana para el Estudio del Higado. EASL-ALEH Clinical 
Practice Guidelines: Non-invasive tests for evaluation of liver 
disease severity and prognosis. J Hepatol 2015; 63: 237-264 [PMID: 
25911335 DOI: 10.1016/j.jhep.2015.04.006]
10  Sagnelli E, Stroffolini T, Sagnelli C, Smedile A, Morisco F, Furlan 
C, Babudieri S, Brancaccio G, Coppola N, Gaeta GB, Almasio PL; 
EPACRON study Group. Epidemiological and clinical scenario of 
chronic liver diseases in Italy: Data from a multicenter nationwide 
survey. Dig Liver Dis 2016; 48: 1066-1071 [PMID: 27291331 
DOI: 10.1016/j.dld.2016.05.014]
May 27, 2018|Volume 10|Issue 5|
Stasi C et al . Epidemiology of chronic viral hepatitis B
 ARTICLE HIGHLIGHTS
416WJH|www.wjgnet.com
11  Stasi C, Silvestri C, Bravi S, Aquilini D, Casprini P, Epifani C, 
Voller F, Cipriani F. Hepatitis B and C epidemiology in an urban 
cohort in Tuscany (Italy). Clin Res Hepatol Gastroenterol 2015; 
39: e13-e15 [PMID: 25001184 DOI: 10.1016/j.clinre.2014.06.002]
12  Navabakhsh B, Mehrabi N, Estakhri A, Mohamadnejad M, 
Poustchi H. Hepatitis B Virus Infection during Pregnancy: 
Transmission and Prevention. Middle East J Dig Dis 2011; 3: 
92-102 [PMID: 25197539]
13  Zhang Z, Chen C, Li Z, Wu YH, Xiao XM. Individualized 
management of pregnant women with high hepatitis B virus DNA 
levels. World J Gastroenterol 2014; 20: 12056-12061 [PMID: 
25232243 DOI: 10.3748/wjg.v20.i34.12056]
14  Zuccaro O, Romanò L, Mele A, Mariano A, Clementi M, Tosti 
ME, Taliani G, Galli C, Zanetti AR, Spada E; Study Group. 
Clinical, epidemiological and virological features of acute hepatitis 
B in Italy. Infection 2015; 43: 431-441 [PMID: 25697541 DOI: 
10.1007/s15010-015-0747-0]
15  Hahné SJ, Veldhuijzen IK, Wiessing L, Lim TA, Salminen 
M, Laar Mv. Infection with hepatitis B and C virus in Europe: 
a systematic review of prevalence and cost-effectiveness of 
screening. BMC Infect Dis 2013; 13: 181 [PMID: 23597411 DOI: 
10.1186/1471-2334-13-181]
16  Liaw YF, Brunetto MR, Hadziyannis S. The natural history of 
chronic HBV infection and geographical differences. Antivir Ther 
2010; 15 Suppl 3: 25-33 [PMID: 21041901 DOI: 10.3851/IMP1621]
17  Sagnelli E, Sagnelli C, Pisaturo M, Macera M, Coppola N. 
Epidemiology of acute and chronic hepatitis B and delta over the 
last 5 decades in Italy. World J Gastroenterol 2014; 20: 7635-7643 
[PMID: 24976701 DOI: 10.3748/wjg.v20.i24.7635]
18  Chu CM, Hung SJ, Lin J, Tai DI, Liaw YF. Natural history of 
hepatitis B e antigen to antibody seroconversion in patients with 
normal serum aminotransferase levels. Am J Med 2004; 116: 
829-834 [PMID: 15178498 DOI: 10.1016/j.amjmed.2003.12.040]
19  Alvarado-Mora MV, Locarnini S, Rizzetto M, Pinho JR. An 
update on HDV: virology, pathogenesis and treatment. Antivir Ther 
2013; 18: 541-548 [PMID: 23792471 DOI: 10.3851/IMP2598]
20  Brunetto MR, Oliveri F, Coco B, Leandro G, Colombatto P, Gorin 
JM, Bonino F. Outcome of anti-HBe positive chronic hepatitis 
B in alpha-interferon treated and untreated patients: a long term 
cohort study. J Hepatol 2002; 36: 263-270 [PMID: 11830339 DOI: 
10.1016/S0168-8278(01)00266-5]
21  Wong GL, Chan HL, Yu Z, Chan HY, Tse CH, Wong VW. Liver 
fibrosis progression is uncommon in patients with inactive chronic 
hepatitis B: a prospective cohort study with paired transient 
elastography examination. J Gastroenterol Hepatol 2013; 28: 
1842-1848 [PMID: 23829381 DOI: 10.1111/jgh.12327]
22  Oliveri F, Surace L, Cavallone D, Colombatto P, Ricco G, Salvati 
N, Coco B, Romagnoli V, Gattai R, Salvati A, Moriconi F, Yuan Q, 
Bonino F, Brunetto MR. Long-term outcome of inactive and active, 
low viraemic HBeAg-negative-hepatitis B virus infection: Benign 
course towards HBsAg clearance. Liver Int 2017; 37: 1622-1631 
[PMID: 28296013 DOI: 10.1111/liv.13416]
23  Stasi C, Salomoni E, Arena U, Corti G, Montalto P, Bartalesi F, 
Marra F, Laffi G, Milani S, Zignego AL, Pinzani M. Non-invasive 
assessment of liver fibrosis in patients with HBV-related chronic 
liver disease undergoing antiviral treatment: A preliminary study. 
Eur J Pharmacol 2017; 806: 105-109 [PMID: 28414057 DOI: 
10.1016/j.ejphar.2017.03.063]
P- Reviewer: Gong ZJ, Zhao HT    S- Editor: Wang XJ 
L- Editor: Filipodia    E- Editor: Tan WW
May 27, 2018|Volume 10|Issue 5|
Stasi C et al . Epidemiology of chronic viral hepatitis B
                                      © 2018 Baishideng Publishing Group Inc. All rights reserved.
Published by Baishideng Publishing Group Inc
7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
Help Desk: http://www.f6publishing.com/helpdesk
http://www.wjgnet.com
